Drug Developers Ask For Flexible Combinations In Co-Development Regulation
Executive Summary
Drug makers responding to FDA's draft guidance on co-development of novel drugs to be used in combination asked the agency to loosen up the boundaries on what kinds of products can be combined, particularly in light of the requirement that the products be aimed only at serious and life-threatening diseases for which there are no satisfactory alternatives.
You may also be interested in...
Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions
In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.
Bill Proposes Offering Exclusivity For Novel Drug Co-Development
Bill proposes six months’ extra marketing exclusivity to spur development of combinations of investigational drugs for serious diseases. Setting aside prospects for passage in an election season, the question is whether that will be enough to get pharma to buy into a risky development space and pioneer a new business model.
Will Progression-Free Survival Cut It In Brave New Melanoma World?
The changing landscape for melanoma drugs raises questions about the appropriateness of overall survival as a trial endpoint and the ethics of using old drugs like the chemotherapy dacarbazine as “standard of care” comparators in pivotal studies.